1.51
-0.16 (-9.58%)
| Penutupan Terdahulu | 1.67 |
| Jumlah Dagangan | 216,897 |
| Harga / Jualan (P/S) | 3.03 |
| Julat 52 Minggu |
| Margin Keuntungan | -197.64% |
| Margin Operasi (TTM) | -123.58% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.60% |
| Nisbah Semasa (MRQ) | 4.46 |
| Aliran Tunai Operasi (OCF TTM) | -136.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.34 M |
| Pulangan Atas Aset (ROA TTM) | -27.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ADC Therapeutics SA | Bercampur | Menurun |
AISkor Stockmoo
| Nilai 35% | -1.7 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -1.7 |
| Masa 35% | 2.6 |
| AI Technical info | NA |
| Osilator Teknikal info | 2.0 |
| Purata Bergerak Teknikal info | 3.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×0.79 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.4% |
| Persetujuan Tonggak | ×0.85 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 0.2 |
| Skor Akhir | 0.21 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.58% |
| % Dimiliki oleh Institusi | 66.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 11,526,710 |
| Tcg Crossover Management, Llc | 30 Jun 2026 | 11,390,175 |
| Prosight Management, Lp | 30 Jun 2026 | 7,824,749 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |